INTERNATIONAL PATENT: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. FILES APPLICATION FOR "PARP1- AND IMMUNE-CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER PATIENTS OVEREXPRESSING UBQLN1 AND/OR UBQLN4"

GENEVA, March 24 -- MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (Hofgartenstr. 880539 Munchen) filed a patent application (PCT/EP2024/075517) for "PARP1- AND IMMUNE-CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER PATIENTS OVEREXPRESSING UBQLN1 AND/OR UBQLN4" on Sep 12, 2024. With publication no. WO/2025/056690, the details related to the patent application was published on Mar 20, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): JACHIMOWICZ, Ron (c/o Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Hofgartenstr. 880539 Munchen), REINHARDT, Christian (c/o Univer...